Pub Date : 2022-09-28DOI: 10.4274/vhd.galenos.2022.2021-12-2
Ç. Mermutluoğlu, M. Bekçibaşı, Ö. Deveci, S. Cerrah, İ. Kaplan, F. Bozkurt, M. Çelen
Investigation the Effects of Total and Total ABSTRACT Objectives: Experimental studies showed the role of oxidative stress in cell destruction and DNA damage in chronic viral hepatitis, In this study, oxidative stress was measured in various clinical forms of chronic hepatitis B (CHB) and the role of oxidative stress was investigated in the development of hepatitis clinic. Materials and Methods: In total, 33 patients with inactive hepatitis B carrier (IHBC), 33 patients with active CHB infection, and 33 healthy adults were included in the study. Serum transaminases [alanine aminotransferase (ALT), aspartate aminotransferase, total antioxidant capacity, and total oxidative stress (TOS)] were measured and compared in the patient groups. Results: In 99 patients were included in the study (56 men, 43 women). The mean age of patients in CHB was 33.21±10.20, in IHBC 36.73±11.54, and the control group 33±11.71. The mean ALT value was 40.93±28.28 U/L in the patients with CHB and 36.33±28.99 U/L in the patients with IHBC. The TOS value115.46±139.64 μm H 2 O 2 equivalent/L in the CHB and 52.67±40.36-μm H 2 O 2 equivalent/L in IHBC. Conclusion: ALT and TOS levels were significantly higher in the CHB than in the other groups. The increased TOS levels in the CHB may be related to the activity of cell destruction in active cases.
总的和总的影响研究摘要目的：实验研究显示了氧化应激在慢性病毒性肝炎细胞破坏和DNA损伤中的作用。在本研究中，测量了各种临床形式的慢性乙型肝炎（CHB）中的氧化应激，并探讨了氧化应激对肝炎临床发展的作用。材料和方法：本研究共纳入33例非活动性乙型肝炎携带者（IHBC）、33例活动性慢性乙型肝炎感染者和33名健康成年人。测量并比较患者组的血清转氨酶[丙氨酸氨基转移酶（ALT）、天冬氨酸氨基转移酶、总抗氧化能力和总氧化应激（TOS）]。结果：99名患者（56名男性，43名女性）被纳入研究。CHB患者的平均年龄为33.21±10.20，IHBC患者为36.73±11.54，对照组为33±11.71。慢性乙型肝炎患者的ALT平均值为40.93±28.28 U/L，IHBC患者为36.33±28.99 U/L。CHB的TOS值为115.46±139.64μm H2 O2当量/L，IHBC为52.67±40.36μm H2 O 2当量/L。结论：慢性乙型肝炎患者ALT和TOS水平明显高于其他各组。CHB中TOS水平的增加可能与活跃病例中的细胞破坏活性有关。
{"title":"Investigation of the Effects of Total Oxidative Stress and Total Antioxidant Capacity on the Prognosis in Patients with Chronic Viral Hepatitis B","authors":"Ç. Mermutluoğlu, M. Bekçibaşı, Ö. Deveci, S. Cerrah, İ. Kaplan, F. Bozkurt, M. Çelen","doi":"10.4274/vhd.galenos.2022.2021-12-2","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2022.2021-12-2","url":null,"abstract":"Investigation the Effects of Total and Total ABSTRACT Objectives: Experimental studies showed the role of oxidative stress in cell destruction and DNA damage in chronic viral hepatitis, In this study, oxidative stress was measured in various clinical forms of chronic hepatitis B (CHB) and the role of oxidative stress was investigated in the development of hepatitis clinic. Materials and Methods: In total, 33 patients with inactive hepatitis B carrier (IHBC), 33 patients with active CHB infection, and 33 healthy adults were included in the study. Serum transaminases [alanine aminotransferase (ALT), aspartate aminotransferase, total antioxidant capacity, and total oxidative stress (TOS)] were measured and compared in the patient groups. Results: In 99 patients were included in the study (56 men, 43 women). The mean age of patients in CHB was 33.21±10.20, in IHBC 36.73±11.54, and the control group 33±11.71. The mean ALT value was 40.93±28.28 U/L in the patients with CHB and 36.33±28.99 U/L in the patients with IHBC. The TOS value115.46±139.64 μm H 2 O 2 equivalent/L in the CHB and 52.67±40.36-μm H 2 O 2 equivalent/L in IHBC. Conclusion: ALT and TOS levels were significantly higher in the CHB than in the other groups. The increased TOS levels in the CHB may be related to the activity of cell destruction in active cases.","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46794015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-28DOI: 10.4274/vhd.galenos.2022.2021-12-1
A. Emecen, H. Caskurlu, P. Ergen, Y. Çağ, F. Arslan, H. Vahaboğlu
Objectives: Patients with hepatitis B e antigen-negative chronic infection (inactive carriers) account for most of the people living with hepatitis B virus (HBV). This study investigated the direct medical cost of monitoring patients within this group. Materials and Methods: A total of 293 outpatients receiving regular monitoring in a large university hospital were included in the study. Direct medical costs included laboratory tests, imaging, liver biopsies and co-payments. Linear mixed effect models were applied to investigate the effect of follow-up time on the annual cost of monitoring. We made quarterly, semi-annual and annual monitoring cost trajectories in accordance with international guideline recommendations. Results: The average annual direct medical cost per patient was 160 USD and the average laboratory visit cost per patient was 68.5 USD. HBV DNA testing contributed to a majority percentage of the total cost (59.6%). As follow-up time increased, the total annual cost ( β =-2.07) and annual cost for DNA testing ( β =-1.03) decreased. The cost trajectory of the first two years of monitoring remained above the semi-annual follow-up strategy. After three years, the cost trajectory of monitoring, while reducing slightly, remained between the semi-annual and annual follow-up strategy trend lines. Conclusion: Due to high-patient numbers, the total cost of monitoring presents a large economic burden. Taking into consideration the generally benign nature of the disease; the length of intervals between outpatient hospital visits could be reviewed and alternative strategies implemented with the aim of reducing expenditure.
{"title":"The Direct Medical Cost of Regular Monitoring of Patients with HBeAg-Negative Chronic Hepatitis B Virus Infection","authors":"A. Emecen, H. Caskurlu, P. Ergen, Y. Çağ, F. Arslan, H. Vahaboğlu","doi":"10.4274/vhd.galenos.2022.2021-12-1","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2022.2021-12-1","url":null,"abstract":"Objectives: Patients with hepatitis B e antigen-negative chronic infection (inactive carriers) account for most of the people living with hepatitis B virus (HBV). This study investigated the direct medical cost of monitoring patients within this group. Materials and Methods: A total of 293 outpatients receiving regular monitoring in a large university hospital were included in the study. Direct medical costs included laboratory tests, imaging, liver biopsies and co-payments. Linear mixed effect models were applied to investigate the effect of follow-up time on the annual cost of monitoring. We made quarterly, semi-annual and annual monitoring cost trajectories in accordance with international guideline recommendations. Results: The average annual direct medical cost per patient was 160 USD and the average laboratory visit cost per patient was 68.5 USD. HBV DNA testing contributed to a majority percentage of the total cost (59.6%). As follow-up time increased, the total annual cost ( β =-2.07) and annual cost for DNA testing ( β =-1.03) decreased. The cost trajectory of the first two years of monitoring remained above the semi-annual follow-up strategy. After three years, the cost trajectory of monitoring, while reducing slightly, remained between the semi-annual and annual follow-up strategy trend lines. Conclusion: Due to high-patient numbers, the total cost of monitoring presents a large economic burden. Taking into consideration the generally benign nature of the disease; the length of intervals between outpatient hospital visits could be reviewed and alternative strategies implemented with the aim of reducing expenditure.","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44894705","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-28DOI: 10.4274/vhd.galenos.2022.2021-2-3
K. Gişi, Murat Ispiroglu, A. Şahin, M. Aral, B. Kantarçeken
Objectives: Chronic hepatitis C virus (HCV) infection still continues to be a significant health problem in the entire world. In addition to this, knowing about the existing genotypes in a region is highly important in terms of guiding antiviral treatment and understanding the epidemiology in that region. In our study, we examined the varying genotype distribution in our region and affecting factors. Materials and Methods: To determine the HCV genotype distribution in Kahramanmaraş in Turkey, patients who were determined to be HCV-positive in the last 4.5 years and whose genotypes were studied retrospectively searched from records and included in the study. Results: Genotype 1 was the most prevalent genotype (47%) in Kahramanmaraş. The second most prevalent (45%) genotype was genotype 3. Additionally, genotypes 2 and 4 were seen at the rates of respectively 2% and 6%. While there was male dominance in genotypes 1, 2, and 3, genotype 4 had female dominance (69%). There was a very high male dominance in genotype 3 (95%), and the mean age of the patients was 26.4. Conclusion: The epidemiology of HCV may show serious variations at locations that receive intense migration and where increased drug usage is observed. The main point in preventing HCV infection should be the identification and elimination of risk factors.
{"title":"Hepatitis C Genotype Distribution Changing Through Years in the Kahramanmaraş Region","authors":"K. Gişi, Murat Ispiroglu, A. Şahin, M. Aral, B. Kantarçeken","doi":"10.4274/vhd.galenos.2022.2021-2-3","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2022.2021-2-3","url":null,"abstract":"Objectives: Chronic hepatitis C virus (HCV) infection still continues to be a significant health problem in the entire world. In addition to this, knowing about the existing genotypes in a region is highly important in terms of guiding antiviral treatment and understanding the epidemiology in that region. In our study, we examined the varying genotype distribution in our region and affecting factors. Materials and Methods: To determine the HCV genotype distribution in Kahramanmaraş in Turkey, patients who were determined to be HCV-positive in the last 4.5 years and whose genotypes were studied retrospectively searched from records and included in the study. Results: Genotype 1 was the most prevalent genotype (47%) in Kahramanmaraş. The second most prevalent (45%) genotype was genotype 3. Additionally, genotypes 2 and 4 were seen at the rates of respectively 2% and 6%. While there was male dominance in genotypes 1, 2, and 3, genotype 4 had female dominance (69%). There was a very high male dominance in genotype 3 (95%), and the mean age of the patients was 26.4. Conclusion: The epidemiology of HCV may show serious variations at locations that receive intense migration and where increased drug usage is observed. The main point in preventing HCV infection should be the identification and elimination of risk factors.","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44916637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-28DOI: 10.4274/vhd.galenos.2022-2021-8-1
M. Bekçibaşı, Eyup Arslan
Objectives: This study identifies the hepatitis delta virus (HDV) antibodies (anti-HDV) seroprevalence in patients with chronic hepatitis B (CHB) infection in a region highly endemic for HDV. Materials and Methods: A total of 306 patients with CHB infection, who were followed up regularly between January 2016 and December 2019, were retrospectively analyzed. Demographic characteristics, hematological parameters, liver function tests, abdominal ultrasonography, hepatitis serologies, and liver biopsy results of the patients were analyzed through patient follow-up forms. Results: Anti-HDV was positive in 43 (14.1%) of 306 patients, 129 (42.1%) of whom were female and had a mean age of 41.5±13.4 years. Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and gamma-glutamil transferase levels of delta hepatitis (DH) patients were significantly higher than those of CHB patients (p=0.019, p<0.001; p=0.027; p=0.001, respectively), whereas albumin, white blood cell, and platelet levels were significantly lower (p<0.001; p=0.001; p<0.001, respectively). 55.8% of patients with DH were with the diagnosed with cirrhosis. Conclusion: Anti-HDV was positive in 14.1% of patients diagnosed with CHB in the Diyarbakır region. The progression to liver cirrhosis and hepatocellular carcinoma is faster in DH; therefore, more efforts should be made to identify and treat this patient group.
{"title":"Anti-HDV Seroprevalence Among Patients with Chronic Hepatitis B Infection in Diyarbakır","authors":"M. Bekçibaşı, Eyup Arslan","doi":"10.4274/vhd.galenos.2022-2021-8-1","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2022-2021-8-1","url":null,"abstract":"Objectives: This study identifies the hepatitis delta virus (HDV) antibodies (anti-HDV) seroprevalence in patients with chronic hepatitis B (CHB) infection in a region highly endemic for HDV. Materials and Methods: A total of 306 patients with CHB infection, who were followed up regularly between January 2016 and December 2019, were retrospectively analyzed. Demographic characteristics, hematological parameters, liver function tests, abdominal ultrasonography, hepatitis serologies, and liver biopsy results of the patients were analyzed through patient follow-up forms. Results: Anti-HDV was positive in 43 (14.1%) of 306 patients, 129 (42.1%) of whom were female and had a mean age of 41.5±13.4 years. Alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and gamma-glutamil transferase levels of delta hepatitis (DH) patients were significantly higher than those of CHB patients (p=0.019, p<0.001; p=0.027; p=0.001, respectively), whereas albumin, white blood cell, and platelet levels were significantly lower (p<0.001; p=0.001; p<0.001, respectively). 55.8% of patients with DH were with the diagnosed with cirrhosis. Conclusion: Anti-HDV was positive in 14.1% of patients diagnosed with CHB in the Diyarbakır region. The progression to liver cirrhosis and hepatocellular carcinoma is faster in DH; therefore, more efforts should be made to identify and treat this patient group.","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44074286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-28DOI: 10.4274/vhd.galenos.2022.2022-4-2
E. Zerdali, İnci Yılmaz Nakir, F. Pehlivanoğlu
Direct-acting Antiviral Agents Responses ABSTRACT Objectives: Direct-acting antiviral (DAA) agents have made a breakthrough for treating chronic hepatitis C virus (HCV) with their high efficacy and tolerability. In this study, the end of treatment response of DAA treatment regimens was analyzed with respect to epidemiological data. Materials and Methods: A total of 143 patients, over 18 years of age, who were treated with the diagnosis of HCV infection were analyzed retrospectively. The comorbid diseases, co-infection status (hepatitis B virus and human immunodeficiency virus-co-infection), genotype distribution and transmission routes were noted. The changes in the laboratory parameters were evaluated before treatment, at the first month and at the end of treatment and after treatment at the 12 th week. Results: When the genotype distributions of the patients were examined, it was found that 75.5% of the patients (n=108) were genotype-1, 4.2% (n=6) were genotype-2, 12.6% (n=18) were genotype-3, 4.9% (n=7) were genotype-4, and 1.4% (n=2) were genotype-5. The treatment regimens of the patients were; paritaprevir + ritonavir + ombitasvir + dasabuvir in 54 (37.8%) patients, ledipasvir + sofosbuvir in 28 (19.6%) patients, glecaprevir + pibrentasvir in 23 (16.1%) patients, and paritaprevir + ritonavir + ombitasvir + dasabuvir + ribavirin (RBV) in 15 (10.5%) patients. Dose reduction was implemented in 31 patients who received RBV treatment. Adverse events were observed in 49.7% (n=71) n of the study population. The rate of sustained viral response-12 (SVR12) was 100% in all treatment regimens. Conclusion: Achieving a SVR12 in chronic HCV decreased all-cause mortality, whether liver-related or unrelated. Second-generation DAAs have been a beacon of hope for humanity in this regard.
{"title":"Evaluation of Direct-acting Antiviral Agents and Clinical Responses in Chronic Hepatitis C Patients","authors":"E. Zerdali, İnci Yılmaz Nakir, F. Pehlivanoğlu","doi":"10.4274/vhd.galenos.2022.2022-4-2","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2022.2022-4-2","url":null,"abstract":"Direct-acting Antiviral Agents Responses ABSTRACT Objectives: Direct-acting antiviral (DAA) agents have made a breakthrough for treating chronic hepatitis C virus (HCV) with their high efficacy and tolerability. In this study, the end of treatment response of DAA treatment regimens was analyzed with respect to epidemiological data. Materials and Methods: A total of 143 patients, over 18 years of age, who were treated with the diagnosis of HCV infection were analyzed retrospectively. The comorbid diseases, co-infection status (hepatitis B virus and human immunodeficiency virus-co-infection), genotype distribution and transmission routes were noted. The changes in the laboratory parameters were evaluated before treatment, at the first month and at the end of treatment and after treatment at the 12 th week. Results: When the genotype distributions of the patients were examined, it was found that 75.5% of the patients (n=108) were genotype-1, 4.2% (n=6) were genotype-2, 12.6% (n=18) were genotype-3, 4.9% (n=7) were genotype-4, and 1.4% (n=2) were genotype-5. The treatment regimens of the patients were; paritaprevir + ritonavir + ombitasvir + dasabuvir in 54 (37.8%) patients, ledipasvir + sofosbuvir in 28 (19.6%) patients, glecaprevir + pibrentasvir in 23 (16.1%) patients, and paritaprevir + ritonavir + ombitasvir + dasabuvir + ribavirin (RBV) in 15 (10.5%) patients. Dose reduction was implemented in 31 patients who received RBV treatment. Adverse events were observed in 49.7% (n=71) n of the study population. The rate of sustained viral response-12 (SVR12) was 100% in all treatment regimens. Conclusion: Achieving a SVR12 in chronic HCV decreased all-cause mortality, whether liver-related or unrelated. Second-generation DAAs have been a beacon of hope for humanity in this regard.","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49404920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-28DOI: 10.4274/vhd.galenos.2022.2022-3-1
Figen Sarıgül Yıldırım, M. Sayan
C the Human ABSTRACT Objectives: Viral hepatitis and human immunodeficiency virus (HIV) infections are still significant causes of morbidity and mortality. This study investigatedaimed to investigate the effect of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection on HIV infection, investigate the epidemiological characteristics of co-infected patients and thus help identify risk factors for coinfection, evaluate the results and clinical information, and shape the treatment of patients. Materials and Methods: This descriptive, cross-sectional study from January 2013 to July 2021 was conducted carried out on 758 patients, including 502 infected with HIV, 196 co-infected with HBV/HCV, and 60 co-infected with HCV/HIV. Comparison between groups in terms of categorical characteristics was analyzed with the Pearson chi-square test or Fisher-Freeman-Halton test. The changes in HIV infection in the presence of co-infections were examined with the multivariate multinomial logistic regression model. Results: We found differences in our HIV-infected patients co- infected with HBV or HCV in gender, nationality, transmission routes, HIV viral load, and CD+4 T-cell count (p<0.001). There was no difference between the groups regarding age, opportunistic infection status, and malignancy status. Conclusion: Our findings indicate that HBV and HCV may affect HIV infection infections. Our approach can focus on these points in co-infected patients, and we can effectively manage their treatment and follow-up.
{"title":"Implications of Hepatitis B and C on the Human Immunodeficiency Virus Infections","authors":"Figen Sarıgül Yıldırım, M. Sayan","doi":"10.4274/vhd.galenos.2022.2022-3-1","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2022.2022-3-1","url":null,"abstract":"C the Human ABSTRACT Objectives: Viral hepatitis and human immunodeficiency virus (HIV) infections are still significant causes of morbidity and mortality. This study investigatedaimed to investigate the effect of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection on HIV infection, investigate the epidemiological characteristics of co-infected patients and thus help identify risk factors for coinfection, evaluate the results and clinical information, and shape the treatment of patients. Materials and Methods: This descriptive, cross-sectional study from January 2013 to July 2021 was conducted carried out on 758 patients, including 502 infected with HIV, 196 co-infected with HBV/HCV, and 60 co-infected with HCV/HIV. Comparison between groups in terms of categorical characteristics was analyzed with the Pearson chi-square test or Fisher-Freeman-Halton test. The changes in HIV infection in the presence of co-infections were examined with the multivariate multinomial logistic regression model. Results: We found differences in our HIV-infected patients co- infected with HBV or HCV in gender, nationality, transmission routes, HIV viral load, and CD+4 T-cell count (p<0.001). There was no difference between the groups regarding age, opportunistic infection status, and malignancy status. Conclusion: Our findings indicate that HBV and HCV may affect HIV infection infections. Our approach can focus on these points in co-infected patients, and we can effectively manage their treatment and follow-up.","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49607461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-28DOI: 10.4274/vhd.galenos.2022.2022-9-1
U. Akarca, N. Baykam, Rahmet Güner, F. Günşar, R. Idilman, S. Kaymakoğlu, İ. Köksal, F. Tabak, T. Yamazhan
After the declaration Global Health Sector Strategy on Viral Hepatitis by the World Health Organization in 2016, the Turkish Government defined a national strategy covering 2018-2023 to reach goals by 2030. Following a participatory decision process and a series of workshops, the strategy was built on eight separate subheadings. Apart from the official Prevention and Control Program, two separate road maps for hepatitis B and C were developed to obtain targets accessible with the cooperation of the Viral Hepatitis Society and the Turkish Association for the Study of the Liver in 2018 and 2020, respectively. Up to 2023, achievements and the current situation of the National Viral Hepatitis Prevention and Control Program and the hepatitis B virus and hepatitis C virus road maps were assessed in detail on June 28th, 2022, by the subject matter experts in Turkey. Besides the officially reported achievement rate (42%) of the Program in 2021, participants mentioned undesirable effects of the coronavirus disease-2019 pandemic, unregulated migration, low levels of professional and public awareness, and barriers to access to anti-viral treatment. Recommendations focused on increasing the efficiency of screening and surveillance by integrating the viral carrier identity of individuals into the national health information system, simplifying the drug supplement and treatment initiation process and insisting on education to raise awareness.
{"title":"Eliminating Viral Hepatitis in Turkey: Achievements and Challenges","authors":"U. Akarca, N. Baykam, Rahmet Güner, F. Günşar, R. Idilman, S. Kaymakoğlu, İ. Köksal, F. Tabak, T. Yamazhan","doi":"10.4274/vhd.galenos.2022.2022-9-1","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2022.2022-9-1","url":null,"abstract":"After the declaration Global Health Sector Strategy on Viral Hepatitis by the World Health Organization in 2016, the Turkish Government defined a national strategy covering 2018-2023 to reach goals by 2030. Following a participatory decision process and a series of workshops, the strategy was built on eight separate subheadings. Apart from the official Prevention and Control Program, two separate road maps for hepatitis B and C were developed to obtain targets accessible with the cooperation of the Viral Hepatitis Society and the Turkish Association for the Study of the Liver in 2018 and 2020, respectively. Up to 2023, achievements and the current situation of the National Viral Hepatitis Prevention and Control Program and the hepatitis B virus and hepatitis C virus road maps were assessed in detail on June 28th, 2022, by the subject matter experts in Turkey. Besides the officially reported achievement rate (42%) of the Program in 2021, participants mentioned undesirable effects of the coronavirus disease-2019 pandemic, unregulated migration, low levels of professional and public awareness, and barriers to access to anti-viral treatment. Recommendations focused on increasing the efficiency of screening and surveillance by integrating the viral carrier identity of individuals into the national health information system, simplifying the drug supplement and treatment initiation process and insisting on education to raise awareness.","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46721046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-09-28DOI: 10.4274/vhd.galenos.2022.2021-9-1
M. Çömez, Tayibe Bal, M. Çabalak
Objectives: Migration can change the demographic dynamics of host populations in terms of communicable diseases in destination countries. This is a potential public health challenge for the health authorities. Hepatitis B virüs (HBV) and hepatitis C virüs (HCV) infections can lead to the development of chronic liver diseases, cirrhosis and hepatocellular carcinoma, whereas human Categorical variables were presented as frequencies (percentages) and compared with chi-square test. Non-normally distributed continuous variables were presented as median with interquartile range (25 th and 75 th percentiles) and compared with the Mann-Whitney U test between the groups. The study is comprised of 54,446 patients, divided into two groups: Turkish patient group (n=20569) and Syrian refugee patient group (n=33877). The of the patients was 41 (28-59) years and 44.8% (n=24396) The epidemiological characteristics and preoperative seroprevalance of HBV, serological markers in the are in 1. Conclusion: Although HBV seroprevalence gradually decreases and HCV and HIV seroprevalence is low; screening, information and treatment programs should be given due importance because of the serious disease potential and preventable conditions with precautions. Additionally, preoperative screening of refugee patients coming for major surgery may be important for the safety of healthcare professionals.
{"title":"What is the Current Situation of HBV, HCV and HIV Seroprevalence Among Syrian Refugees? Patients Evaluated Preoperatively Over Ten Years","authors":"M. Çömez, Tayibe Bal, M. Çabalak","doi":"10.4274/vhd.galenos.2022.2021-9-1","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2022.2021-9-1","url":null,"abstract":"Objectives: Migration can change the demographic dynamics of host populations in terms of communicable diseases in destination countries. This is a potential public health challenge for the health authorities. Hepatitis B virüs (HBV) and hepatitis C virüs (HCV) infections can lead to the development of chronic liver diseases, cirrhosis and hepatocellular carcinoma, whereas human Categorical variables were presented as frequencies (percentages) and compared with chi-square test. Non-normally distributed continuous variables were presented as median with interquartile range (25 th and 75 th percentiles) and compared with the Mann-Whitney U test between the groups. The study is comprised of 54,446 patients, divided into two groups: Turkish patient group (n=20569) and Syrian refugee patient group (n=33877). The of the patients was 41 (28-59) years and 44.8% (n=24396) The epidemiological characteristics and preoperative seroprevalance of HBV, serological markers in the are in 1. Conclusion: Although HBV seroprevalence gradually decreases and HCV and HIV seroprevalence is low; screening, information and treatment programs should be given due importance because of the serious disease potential and preventable conditions with precautions. Additionally, preoperative screening of refugee patients coming for major surgery may be important for the safety of healthcare professionals.","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42919918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-04-01DOI: 10.4274/vhd.galenos.2022.2021-8-2
N. Aydın, İ. Köksal
{"title":"An Evaluation of Chronic Hepatitis C Patients’ Responses to Direct-Acting Antivirals According to Transient Elastography and Serum Biomarkers","authors":"N. Aydın, İ. Köksal","doi":"10.4274/vhd.galenos.2022.2021-8-2","DOIUrl":"https://doi.org/10.4274/vhd.galenos.2022.2021-8-2","url":null,"abstract":"","PeriodicalId":42346,"journal":{"name":"Viral Hepatit Dergisi-Viral Hepatitis Journal","volume":" ","pages":""},"PeriodicalIF":0.1,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49608245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：